Wealth Enhancement Advisory Services LLC Has $268.98 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Johnson & Johnson by 1.5%, owning approximately 1.72 million shares valued at nearly $269 million as of its latest SEC filing.
• Frequent institutional investors, including Vanguard Group and Bank of New York Mellon Corp, also increased their positions in Johnson & Johnson, contributing to over 69% of the stock being owned by institutional investors.
• Analysts have raised their price targets for Johnson & Johnson, with a consensus rating of “Moderate Buy” and a target price around $177.87, indicating positive market expectations.

Wealth Enhancement Advisory Services LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,724,086 shares of the company's stock after purchasing an additional 25,255 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.07% of Johnson & Johnson worth $268,975,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $1.81 during trading hours on Friday, reaching $175.97. 25,617,065 shares of the company traded hands, compared to its average volume of 6,995,150. The firm's 50-day moving average is $172.80 and its 200-day moving average is $161.67. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market cap of $423.80 billion, a P/E ratio of 18.82, a P/E/G ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. Bank of America boosted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $177.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.